RNA-binding motif protein 24 inhibits HBV replication in vivo.
RNA binding motif protein 24
adeno-associated virus vector
functional cure
hepatitis B virus
replication
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
07
07
2023
received:
20
05
2023
accepted:
08
07
2023
medline:
25
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
ppublish
Résumé
Despite the extensive use of effective vaccines and antiviral drugs, chronic hepatitis B virus (HBV) infection continues to pose a serious threat to global public health. Therapies with novel mechanisms of action against HBV are being explored for achieving a functional cure. In this study, five murine models of HBV replication were used to investigate the inhibitory effect of RNA binding motif protein 24 (RBM24) on HBV replication. The findings revealed that RBM24 serves as a host restriction factor and suppresses HBV replication in vivo. The transient overexpression of RBM24 in hydrodynamics-based mouse models of HBV replication driven by the CMV or HBV promoters suppressed HBV replication. Additionally, the ectopic expression of RBM24 decreased viral accumulation and the levels of HBV covalently closed circular DNA (cccDNA) in an rcccDNA mouse model. The liver-directed transduction of adeno-associated viruses (AAV)-RBM24 mediated the stable hepatic expression of RBM24 in pAAV-HBV1.2 and HBV/tg mouse models, and markedly reduced the levels of HBV cccDNA and other viral indicators. Altogether, these findings revealed that RBM24 inhibits the replication of HBV in vivo, and RBM24 may be a potential therapeutic target for combating HBV infections.
Substances chimiques
DNA, Circular
0
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28969Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479-480:672-686. doi:10.1016/j.virol.2015.02.031
Nguyen DH, Ludgate L, Hu J. Hepatitis B virus-cell interactions and pathogenesis. J Cell Physiol. 2008;216:289-294. doi:10.1002/jcp.21416
Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res. 2008;134:235-249. doi:10.1016/j.virusres.2007.12.024
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117-171. doi:10.1016/S0140-6736(14)61682-2
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546-1555. doi:10.1016/S0140-6736(15)61412-X
Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383-403. doi:10.1016/S2468-1253(18)30056-6
Le LV, Blach S, Rewari B, et al. Progress towards achieving viral hepatitis B and C elimination in the Asia and pacific region: results from modelling and global reporting. Liver Int. 2022;42:1930-1934. doi:10.1111/liv.15131
Wong GLH, Gane E, Lok ASF. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76:1249-1262. doi:10.1016/j.jhep.2021.11.024
Mahajan S, Choudhary S, Kumar P, Tomar S. Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens. Bioorg Med Chem. 2021;46:116356. doi:10.1016/j.bmc.2021.116356
Zhang W, Chen J, Wu M, et al. PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. Hepatology. 2017;66:398-415. doi:10.1002/hep.29133
Liu Y, Nie H, Mao R, et al. Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA. PLoS Pathog. 2017;13:e1006296. doi:10.1371/journal.ppat.1006296
Mao R, Nie H, Cai D, et al. Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog. 2013;9:e1003494. doi:10.1371/journal.ppat.1003494
Belloni L, Pollicino T, De Nicola F, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci. 2009;106:19975-19979. doi:10.1073/pnas.0908365106
Xing T, Zhu J, Xian J, et al. miRNA-548ah promotes the replication and expression of hepatitis B virus by targeting histone deacetylase 4. Life Sci. 2019;219:199-208. doi:10.1016/j.lfs.2018.12.057
Yuan Y, Zhao K, Yao Y, et al. HDAC11 restricts HBV replication through epigenetic repression of cccDNA transcription. Antiviral Res. 2019;172:104619. doi:10.1016/j.antiviral.2019.104619
Ren JH, Hu JL, Cheng ST, et al. SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3-9 homolog 1 and SET domain containing 1A histone methyltransferases. Hepatology. 2018;68:1260-1276. doi:10.1002/hep.29912
Yao Y, Yang B, Cao H, et al. RBM24 stabilizes hepatitis B virus pregenomic RNA but inhibits core protein translation by targeting the terminal redundancy sequence. Emerg Microbes Infect. 2018;7:1-14. doi:10.1038/s41426-018-0091-4
Yao Y, Yang B, Chen Y, et al. RNA-binding motif protein 24 (RBM24) is involved in pregenomic RNA packaging by mediating interaction between hepatitis B virus polymerase and the epsilon element. J Virol. 2019;93(6):e02161-18. doi:10.1128/JVI.02161-18
Pontoizeau C, Simon-Sola M, Gaborit C, et al. Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice. Nat Commun. 2022;13:3278. doi:10.1038/s41467-022-30880-w
Li Y, He M, Wang Z, et al. STING signaling activation inhibits HBV replication and attenuates the severity of liver injury and HBV-induced fibrosis. Cell Mol Immunol. 2022;19:92-107. doi:10.1038/s41423-021-00801-w
Qi Z, Li G, Hu H, et al. Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice. J Virol. 2014;88:8045-8056. doi:10.1128/JVI.01024-14
Li G, Zhu Y, Shao D, et al. Recombinant covalently closed circular DNA of hepatitis B virus induces long-term viral persistence with chronic hepatitis in a mouse model. Hepatology. 2018;67:56-70. doi:10.1002/hep.29406
Wu LL, Wang HY, Chen PJ. Hydrodynamic HBV transfection mouse model. Methods Mol Biol. 2017;1540:227-235. doi:10.1007/978-1-4939-6700-1_19
Liu S, Zhao K, Su X, et al. Enhanced host immune responses in presence of HCV facilitate HBV clearance in coinfection. Virologica Sinica. 2022;37:408-417. doi:10.1016/j.virs.2022.04.001
Chen Y, Yao Y, Zhao K, et al. DNA repair factor poly(ADP-ribose) polymerase 1 is a proviral factor in hepatitis B virus covalently closed circular DNA formation. J Virol. 2022;96:e0058522. doi:10.1128/jvi.00585-22
Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12:341-355. doi:10.1038/nrg2988
Li L, Li S, Zhou Y, et al. The dose of HBV genome contained plasmid has a great impact on HBV persistence in hydrodynamic injection mouse model. Virol J. 2017;14:205. doi:10.1186/s12985-017-0874-6
Cornberg M, Lok ASF, Terrault NA, 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B-report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. J Hepatol. 2020;72:539-557. doi:10.1016/j.jhep.2019.11.003
Ren H, Huang Y. Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B. J Viral Hepatitis. 2019;26(suppl 1):5-31. doi:10.1111/jvh.13150
Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology. 2012;143:629-636. doi:10.1053/j.gastro.2012.05.039
Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol. 2019;71:900-907. doi:10.1016/j.jhep.2019.06.028
Yao Y, Yang B, Chen Y, et al. RNA-Binding motif protein 38 (RBM38) mediates HBV pgRNA packaging into the nucleocapsid. Antiviral Res. 2022;198:105249. doi:10.1016/j.antiviral.2022.105249
Suda T, Liu D. Hydrodynamic gene delivery: its principles and applications. Mol Ther. 2007;15:2063-2069. doi:10.1038/sj.mt.6300314